Picture of Bioventus logo

BVS Bioventus News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapSuper Stock

Bioventus Inc expected to post earnings of 2 cents a share - Earnings Preview

* Bioventus Inc  BVS.OQ   BVS.O  is expected to show a fall
in
quarterly revenue when it reports  results on March 12 for the
period ending December 31 2023
    * The Durham North Carolina-based  company is expected to
report a
1.5% decrease in revenue to $123.958 million from $125.83
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Bioventus Inc is for
earnings
of 2 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bioventus
Inc is
$6.50​, above​ its last closing price of $5.52. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.02       -0.02      0.05      Beat    350
 Jun. 30 2023  0.01        0.00       0.14      Beat    
 Mar. 31 2023  -0.15       -0.15      -0.26     Missed  -73.3​
 Dec. 31 2022  0.05        0.05       -0.06     Missed  -226.3
 ​​Sep.        0.12        0.12       0.08      Missed  -34.4
 30 2022                                                
 Jun. 30 2022  0.15        0.16       0.10      Missed  -35.9​
 Mar. 31 2022  0.05        0.05       0.04      Missed  -16.7
 Dec. 31 2021  0.17        0.18       0.26      Beat    46.5
 This summary was machine generated March 8 at 13:18 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Bioventus

See all news